Clincosm LogoSign in Get a demo

SCINTI-COVID: Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients.

Sponsor
University Hospital, Brest (Other)
Overall Status
Completed
CT.gov ID
NCT05353608
Collaborator
(none)
183
Enrollment
2
Locations
1
Actual Duration (Months)
91.5
Patients Per Site
89.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A frequent complication of COVID-19 disease is pulmonary embolism (PE).

Lung ventilation/perfusion (V/P) scintigraphy is a well-established test for PE diagnosis. The test is interpreted based on the recognition of wedge shaped perfusion mismatched defects. However, the ventilation procedure increases the potential risk of contamination by the aerosol secretion and the expired air.

A variety of strategies have been proposed in the nuclear medicine literature regarding performance of lung ventilation scintigraphy in COVID-19 patients with suspected acute PE. However, there is currently no factual data in this specific population to support recommendations to the nuclear medicine community.

The aim of this study was to assess the role of ventilation imaging when performing lung scintigraphy for suspected PE in COVID-19 patients.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    183 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients: a Multicenter Observational Study.
    Actual Study Start Date :
    Apr 30, 2021
    Actual Primary Completion Date :
    May 31, 2021
    Actual Study Completion Date :
    May 31, 2021

    Outcome Measures

    Primary Outcome Measures

    1. PE diagnosis on lung scintigraphy without the ventilation scan. [1 day]

      Percentage of scans for which the diagnostic conclusion of the lung scan would have been different when omitting the ventilation scan

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Patients with suspected COVID-19 disease

    • Referred for lung scintigraphy for suspected acute PE

    Exclusion Criteria:

    • Patient under guardianship or curatorship

    • Patient deprived of liberty by an administrative or judicial decision

    • Inability or refuse to give consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHRU de Brest Brest France 29609
    2 Cnetre Jean-Perrin Clermont-Ferrand France

    Sponsors and Collaborators

    • University Hospital, Brest

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Brest
    ClinicalTrials.gov Identifier:
    NCT05353608
    Other Study ID Numbers:
    • SCINTI-COVID (29BRC21.0143)
    First Posted:
    Apr 29, 2022
    Last Update Posted:
    Apr 29, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Brest
    Lung scintigraphy
    Additional relevant MeSH terms:
    COVID-19
    Pulmonary Embolism
    Embolism

    Study Results

    No Results Posted as of Apr 29, 2022